These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 458586)

  • 1. Pharmacokinetics of drugs subject to enterohepatic circulation.
    Chen HS; Gross JF
    J Pharm Sci; 1979 Jun; 68(6):792-4. PubMed ID: 458586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cholestasis on drug elimination: pharmacokinetics.
    Harrison LI; Gibaldi M
    J Pharm Sci; 1976 Sep; 65(9):1346-8. PubMed ID: 966151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A time-lag model for pharmacokinetics of drugs subject to enterohepatic circulation.
    Steimer JL; Plusquellec Y; Guillaume A; Boisvieux JF
    J Pharm Sci; 1982 Mar; 71(3):297-302. PubMed ID: 7069584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reversible clearance model for the enterohepatic circulation of drug and conjugate metabolite pair.
    Semmes RL; Shen DD
    Drug Metab Dispos; 1990; 18(1):80-7. PubMed ID: 1970782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of enterohepatic recirculation in drug disposition: cooperation and complications.
    Malik MY; Jaiswal S; Sharma A; Shukla M; Lal J
    Drug Metab Rev; 2016 May; 48(2):281-327. PubMed ID: 26987379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the fraction reabsorbed in drugs undergoing enterohepatic circulation.
    Tse FL; Ballard F; Skinn J
    J Pharmacokinet Biopharm; 1982 Aug; 10(4):455-61. PubMed ID: 7153875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologically Based Pharmacokinetic Modeling.
    Toshimoto K; Tomoda Y; Chiba K; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2727-2738. PubMed ID: 28479365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose.
    Garrett ER; Jackson AJ
    J Pharm Sci; 1979 Jun; 68(6):753-71. PubMed ID: 458581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary excretion of drugs in man.
    Rollins DE; Klaassen CD
    Clin Pharmacokinet; 1979; 4(5):368-79. PubMed ID: 389528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variable reabsorption time-delay model for pharmacokinetics of drugs.
    Labat C; Mansour K; Malmary MF; Terrissol M; Oustrin J
    Eur J Drug Metab Pharmacokinet; 1987; 12(2):129-33. PubMed ID: 3691578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of delta9-tetrahydrocannabinol in dogs.
    Garrett ER; Hunt CA
    J Pharm Sci; 1977 Mar; 66(3):395-407. PubMed ID: 845807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug recirculation model with multiple cycles occurring at unequal time intervals.
    Plusquellec Y; Houin G
    J Biomed Eng; 1992 Nov; 14(6):521-6. PubMed ID: 1434577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical method for monitoring drug excretion and enterohepatic circulation in the rat.
    Tse FL; Ballard F; Jaffe JM
    J Pharmacol Methods; 1982 Mar; 7(2):139-44. PubMed ID: 7098496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation and time to steady state for drugs subject to enterohepatic cycling: a stimulation study.
    Shepard TA; Gannaway DJ; Lockwood GF
    J Pharm Sci; 1985 Dec; 74(12):1331-3. PubMed ID: 4087202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the effective amount entering the body for drugs subject to enterohepatic recirculations.
    Plusquellec Y; Houin G
    Med Eng Phys; 1995 Apr; 17(3):172-6. PubMed ID: 7795853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A stochastic approach in the evaluation of plasma curves with enterohepatic recycling.
    Tarr M; Eöry A
    Arch Toxicol Suppl; 1985; 8():208-10. PubMed ID: 3868351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of area under the curve measurements for drugs subject to enterohepatic cycling.
    Shepard TA; Reuning RH; Aarons LJ
    J Pharm Sci; 1985 Feb; 74(2):227-8. PubMed ID: 3989699
    [No Abstract]   [Full Text] [Related]  

  • 18. Estimation of area under the curve for drugs subject to enterohepatic cycling.
    Shepard TA; Reuning RH; Aarons LJ
    J Pharmacokinet Biopharm; 1985 Dec; 13(6):589-608. PubMed ID: 3834073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-delay for two-compartment models used for study of enterohepatic circulation of drugs.
    Plusquellec Y; Bousquet L
    IEEE Trans Biomed Eng; 1984 Jun; 31(6):469-72. PubMed ID: 6735419
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficiency of enterohepatic circulation, its determination and influence on drug bioavailability.
    Horkovics-Kovats S
    Arzneimittelforschung; 1999 Oct; 49(10):805-15. PubMed ID: 10554656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.